Veterans and servicemembers get Medicare drug prices—no more paying extra
H.R. 8667 — MISSION Rx Act · Filed by Eugene Vindman (D-VA) · 15 cosponsors · Introduced May 7, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps what servicemembers, veterans, and federal agencies pay for prescription drugs covered under Medicare's Drug Price Negotiation Program. Specifically, TRICARE beneficiaries and veterans cannot pay more in copayments than Medicare Part D beneficiaries pay for the same negotiated drugs, and federal agencies procuring those drugs must respect the maximum fair prices set by the negotiation program.
Why we flagged it
The bill's core function is to harmonize cost-sharing and procurement prices across TRICARE, VA, and federal agencies by tying them to Medicare's negotiated drug prices. It is a price-control measure targeting federal populations and procurement, not a general healthcare reform.
What the text implies
- The bill creates a permanent linkage between TRICARE/VA cost-sharing and Medicare Part D negotiated prices. If Medicare's negotiation program is terminated or modified, the bill includes a conforming amendment requiring VA master agreements to revert to 'existing law' pricing—but 'existing law' is undefined and may create ambiguity in future disputes.
- Federal agencies procuring selected drugs must now respect the maximum fair price set by Medicare's negotiation program. This extends Medicare's negotiating power into federal procurement (DoD, VA, other agencies), potentially amplifying the program's leverage over manufacturers but also creating cross-agency pricing dependencies.
The full analysis lists 4 implications of this text.
Who stands to gain
servicemembers and their families (TRICARE beneficiaries); veterans and their families (VA beneficiaries); U.S. federal government (reduced procurement costs)